(New York and Washington, D.C.) – Akin advised Pharmakon Advisors, LP and its affiliated funds in providing a senior secured term loan of up to $250 million in two tranches to UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. The initial tranche of $200 million was funded at closing to refinance UroGen’s existing $125 million debt facility and provide additional non-dilutive capital.
The Akin team was led by tax partner Geoffrey Secol and included fellow tax partner Stuart Leblang; and health care & life sciences partner Nathan Brown, senior counsel Jo-Ellyn Klein and counsel Emily Gerry and Caroline Kessler.
For additional information on the transaction, please click here.
Akin is a leading international law firm with more than 1,000 lawyers in offices throughout the United States, Europe, Asia and the Middle East.
# # #
© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.